Alcon (ALC) Reports Q4 Earnings: What Key Metrics Have to Say
Werte in diesem Artikel
Alcon (ALC) reported $2.48 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 6.2%. EPS of $0.72 for the same period compares to $0.70 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $2.46 billion, representing a surprise of +0.70%. The company delivered an EPS surprise of +2.86%, with the consensus EPS estimate being $0.70.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Alcon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net sales by region- International: $1.37 billion versus $1.37 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +8.1% change. Net sales by region- United States: $1.11 billion compared to the $1.09 billion average estimate based on two analysts. Net Sales- Total Surgical: $1.42 billion compared to the $1.41 billion average estimate based on four analysts. The reported number represents a change of +5.3% year over year. Net Sales- Total Vision care: $1.05 billion versus the four-analyst average estimate of $1.05 billion. The reported number represents a year-over-year change of +7.6%. Net Sales- Total Surgical- Consumables: $738 million versus $727.70 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.3% change. Net Sales- Total Surgical- Equipment/other: $229 million versus the four-analyst average estimate of $224.83 million. The reported number represents a year-over-year change of +1.3%. Net Sales- Total Vision Care- Contact lenses: $638 million versus the four-analyst average estimate of $625.72 million. The reported number represents a year-over-year change of +10.2%. Net Sales- Total Vision Care- Ocular health: $416 million versus the four-analyst average estimate of $427.05 million. The reported number represents a year-over-year change of +3.7%. Net Sales- Total Surgical- Implantables: $456 million versus $456.52 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4.1% change. Revenues- Other revenues: $25 million versus $19.64 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +25% change. View all Key Company Metrics for Alcon here>>>Shares of Alcon have returned -2.2% over the past month versus the Zacks S&P 500 composite's -1.8% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alcon (ALC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Ausgewählte Hebelprodukte auf Novartis
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Novartis
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Novartis AG
Analysen zu Novartis AG
Datum | Rating | Analyst | |
---|---|---|---|
25.02.2025 | Novartis Neutral | JP Morgan Chase & Co. | |
20.02.2025 | Novartis Outperform | Bernstein Research | |
18.02.2025 | Novartis Buy | Deutsche Bank AG | |
13.02.2025 | Novartis Neutral | UBS AG | |
12.02.2025 | Novartis Buy | Deutsche Bank AG |
Datum | Rating | Analyst | |
---|---|---|---|
20.02.2025 | Novartis Outperform | Bernstein Research | |
18.02.2025 | Novartis Buy | Deutsche Bank AG | |
12.02.2025 | Novartis Buy | Deutsche Bank AG | |
04.02.2025 | Novartis Buy | Deutsche Bank AG | |
03.02.2025 | Novartis Kaufen | DZ BANK |
Datum | Rating | Analyst | |
---|---|---|---|
25.02.2025 | Novartis Neutral | JP Morgan Chase & Co. | |
13.02.2025 | Novartis Neutral | UBS AG | |
11.02.2025 | Novartis Neutral | Goldman Sachs Group Inc. | |
06.02.2025 | Novartis Neutral | Goldman Sachs Group Inc. | |
03.02.2025 | Novartis Hold | Deutsche Bank AG |
Datum | Rating | Analyst | |
---|---|---|---|
21.11.2024 | Novartis Underweight | Barclays Capital | |
24.06.2024 | Novartis Underweight | Barclays Capital | |
23.04.2024 | Novartis Underweight | Barclays Capital | |
28.03.2024 | Novartis Underweight | Barclays Capital | |
06.02.2024 | Novartis Underweight | Barclays Capital |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novartis AG nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen